MA50359A - Anticorps anti-cd38 et procédés d'utilisation - Google Patents

Anticorps anti-cd38 et procédés d'utilisation

Info

Publication number: MA50359A
Authority: MA; Morocco
Prior art keywords: antibodies; methods
Prior art date: 2017-10-10

Application number

MA050359A

Other languages

English (en)

Inventor

Béatrice Cameron

Tarik Dabdoubi

Cendrine Lemoine

Gary Nabel

Catherine Prades

Edward Seung

Ronnie Wei

Lan Wu

Ling Xu

Zhi-Yong Yang

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-10

Filing date

2018-10-09

Publication date

2020-08-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63963620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50359(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-10-09 Application filed by Sanofi Sa filed Critical Sanofi Sa

2020-08-19 Publication of MA50359A publication Critical patent/MA50359A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Communicable Diseases (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Pulmonology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

MA050359A 2017-10-10 2018-10-09 Anticorps anti-cd38 et procédés d'utilisation MA50359A (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US201762570655P	2017-10-10	2017-10-10
US201762570660P	2017-10-11	2017-10-11
US201862676221P	2018-05-24	2018-05-24
EP18187186		2018-08-03

Publications (1)

Publication Number	Publication Date
MA50359A true MA50359A (fr)	2020-08-19

Family

ID=63963620

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050359A MA50359A (fr)	2017-10-10	2018-10-09	Anticorps anti-cd38 et procédés d'utilisation

Country Status (20)

Country	Link
US (3)	US11186649B2 (fr)
EP (2)	EP3694882B1 (fr)
JP (4)	JP7036909B2 (fr)
KR (1)	KR20200061402A (fr)
CN (4)	CN120058938A (fr)
AR (1)	AR116718A1 (fr)
AU (1)	AU2018348093A1 (fr)
BR (1)	BR112020007002A2 (fr)
CA (1)	CA3078800A1 (fr)
ES (1)	ES2986579T3 (fr)
IL (1)	IL273871A (fr)
MA (1)	MA50359A (fr)
MX (1)	MX2020004129A (fr)
MY (1)	MY199781A (fr)
PH (1)	PH12020550408A1 (fr)
PY (1)	PY1888702A (fr)
SG (1)	SG11202003212PA (fr)
TW (4)	TW202432580A (fr)
UY (1)	UY37928A (fr)
WO (1)	WO2019074973A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1914242A1 (fr) *	2006-10-19	2008-04-23	Sanofi-Aventis	Nouveau anticorps Anti-CD38 pour le traitement du cancer
TWI588156B (zh) *	2011-03-28	2017-06-21	賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
US12466897B2 (en)	2011-10-10	2025-11-11	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN105051069B (zh)	2013-01-14	2019-12-10	Xencor股份有限公司	新型异二聚体蛋白
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
CA2967426A1 (fr)	2014-11-26	2016-06-02	Xencor, Inc.	Anticorps heterodimeriques se liant a l'antigene cd3 et a un antigene tumoral
BR112017011166A2 (pt)	2014-11-26	2018-02-27	Xencor, Inc.	anticorpos heterodiméricos que se ligam a cd3 e cd38
MY191964A (en) *	2015-01-23	2022-07-21	Sanofi Sa	Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
MX2018005048A (es)	2015-10-25	2018-09-06	Sanofi Sa	Proteinas de union triespecificas y/o trivalantes para la prevencion o el tratamiento de la infeccion por vih.
BR112018070998A2 (pt)	2016-04-13	2019-02-26	Sanofi	proteínas de ligação triespecíficas e/ou trivalentes
SI3443006T1 (sl)	2016-04-13	2024-01-31	Sanofi	Trispecifični in/ali trivalentni vezni proteini
MX2018016265A (es)	2016-06-28	2019-07-04	Xencor Inc	Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
BR112019012354A2 (pt)	2016-12-21	2019-11-26	Teneobio, Inc.	anticorpos apenas de cadeia pesada anti-bcma
CN110891971B (zh)	2017-06-20	2024-01-12	特尼奥生物股份有限公司	仅有重链的抗bcma抗体
CN120058938A (zh) *	2017-10-10	2025-05-30	赛诺菲	抗cd38抗体及与抗cd3和抗cd28抗体的组合
KR20200085828A (ko)	2017-11-08	2020-07-15	젠코어 인코포레이티드	신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
EP3773911A2 (fr)	2018-04-04	2021-02-17	Xencor, Inc.	Anticorps hétérodimères qui se lient à la protéine d'activation des fibroblastes
MA52366A (fr)	2018-04-25	2021-03-03	Prometheus Biosciences Inc	Anticorps anti-tl1a optimisés
MX2021004147A (es) *	2018-10-09	2021-09-08	Sanofi Sa	Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
AU2020252556B2 (en)	2019-04-05	2026-02-05	Teneobio, Inc.	Heavy chain antibodies binding to PSMA
US11613576B2 (en)	2019-04-09	2023-03-28	Sanofi	Trispecific binding proteins, methods, and uses thereof
CN113950484B (zh) *	2019-04-09	2025-07-29	赛诺菲	三特异性结合蛋白、其方法和用途
WO2021003074A1 (fr) *	2019-07-03	2021-01-07	Crystal Bioscience Inc.	Anticorps anti-cd38 et ses procédés d'utilisation
CN118924895A (zh) *	2019-08-30	2024-11-12	蜻蜓疗法股份有限公司	用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
PH12022550978A1 (en)	2019-10-24	2023-10-09	Cedars Sinai Medical Center	Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
EP4048690A1 (fr)	2019-10-25	2022-08-31	Sanofi	Procédés d'analyse du mésappariement de chaîne dans des protéines de liaison multispécifiques
CN112876563B (zh) *	2019-11-29	2022-08-16	康诺亚生物医药科技（成都）有限公司	药物组合物及其制备方法和应用
MX2022013453A (es)	2020-04-29	2022-11-16	Teneobio Inc	Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas.
UY40898A (es) *	2020-04-29	2024-10-15	Teneobio Inc	Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
US11919956B2 (en)	2020-05-14	2024-03-05	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
JP7773528B2 (ja)	2020-08-19	2025-11-19	ゼンコアインコーポレイテッド	抗ｃｄ２８組成物
CN116348495A (zh) *	2020-09-18	2023-06-27	瑞泽恩制药公司	结合cd38和/或cd28的抗原结合分子及其用途
CA3172530A1 (fr)	2021-02-25	2022-09-01	Spencer PARK	Recepteur antigenique chimerique ciblant ror1
CA3212665A1 (fr)	2021-03-09	2022-09-15	Xencor, Inc.	Anticorps heterodimeriques se liant a cd3 et a cldn6
KR20230154311A (ko)	2021-03-10	2023-11-07	젠코어 인코포레이티드	Cd3 및 gpc3에 결합하는 이종이량체 항체
TW202325743A (zh) *	2021-07-14	2023-07-01	大陸商江蘇恆瑞醫藥股份有限公司	特異性結合ｃｄ３８、ｂｃｍａ和ｃｄ３的抗原結合分子及其醫藥用途
US20250277051A1 (en) *	2021-08-02	2025-09-04	Hangzhou Unogen Biotech, Ltd	Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
WO2023021477A1 (fr) *	2021-08-20	2023-02-23	Novartis Ag	Procédés de fabrication de cellules exprimant un récepteur antigénique chimérique
US12365743B2 (en)	2022-02-23	2025-07-22	Xencor, Inc.	Anti-CD28 x anti-PSMA antibodies
JP2025522482A (ja)	2022-06-17	2025-07-15	アポジーバイオロジクス，インコーポレイテッド	インターロイキン１３に結合する抗体及び使用方法
CN119487071A (zh) *	2022-06-24	2025-02-18	北京可瑞生物科技有限公司	基于t细胞受体的双特异性多肽分子及其用途
EP4688860A2 (fr) *	2023-03-28	2026-02-11	Nkarta, Inc.	Anticorps et récepteurs antigéniques chimériques spécifiques pour cd38
WO2025027003A1 (fr)	2023-07-31	2025-02-06	Sanofi	Méthodes et utilisations pour des activateurs de lymphocytes t anti-cd38 dans le traitement de lymphomes t périphériques
WO2025209594A1 (fr) *	2024-04-06	2025-10-09	华深智药生物科技(苏州)有限公司	Anticorps anti-gucy2c et utilisation d'anticorps multi-spécifique
WO2025209593A1 (fr) *	2024-04-06	2025-10-09	华深智药生物科技(苏州)有限公司	Activateur de lymphocytes t à anticorps multi-spécifiques
WO2026019667A1 (fr) *	2024-07-17	2026-01-22	Jn Biosciences Llc	Anticorps trispécifiques pour l'activation de cellules immunitaires

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2058199T3 (es)	1987-09-23	1994-11-01	Bristol Myers Squibb Co	Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
DE69937291T2 (de)	1998-04-02	2008-07-10	Genentech, Inc., South San Francisco	Antikörpervarianten und fragmente davon
CN1294148C (zh)	2001-04-11	2007-01-10	中国科学院遗传与发育生物学研究所	环状单链三特异抗体
EP2395016A3 (fr) *	2003-05-30	2012-12-19	Merus B.V.	Conception et utilisation de régions variables appariées de molécules de liaison spécifiques
US20050163782A1 (en) *	2003-06-27	2005-07-28	Biogen Idec Ma Inc.	Modified binding molecules comprising connecting peptides
US9200061B2 (en) *	2004-02-06	2015-12-01	Morpho Sys AG	Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
NZ548990A (en) *	2004-02-06	2009-06-26	Morphosys Ag	Anti-CD38 human antibodies and uses therefor
CN100376599C (zh)	2004-04-01	2008-03-26	北京安波特基因工程技术有限公司	基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP3312196B1 (fr) *	2005-03-23	2019-07-17	Genmab A/S	Anticorps dirigés contre cd38 pour le traitement du myélome multiple
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
EP1914242A1 (fr) *	2006-10-19	2008-04-23	Sanofi-Aventis	Nouveau anticorps Anti-CD38 pour le traitement du cancer
EP2050764A1 (fr)	2007-10-15	2009-04-22	sanofi-aventis	Nouveau format d'anticorps bispécifique polyvalent
JP2011523853A (ja)	2008-06-03	2011-08-25	アボット・ラボラトリーズ	二重可変ドメイン免疫グロブリン及びその使用
EP2480572B1 (fr)	2009-09-25	2019-01-30	The United States of America, as represented by The Secretary, Department of Health and Human Services	Anticorps neutralisants dirigés contre le vih-1 et utilisation associée
EP3613774A1 (fr)	2010-06-09	2020-02-26	Genmab A/S	Anticorps diriges contre le cd38 humain
JOP20210044A1 (ar) *	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
TWI588156B (zh)	2011-03-28	2017-06-21	賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (fr)	2011-05-09	2012-11-15	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Anticorps neutralisants anti-vih-1 et leur utilisation
AU2012255266B2 (en)	2011-05-17	2017-05-25	California Institute Of Technology	Human immunodeficiency virus neutralizing antibodies and methods of use thereof
RU2624046C2 (ru)	2011-11-07	2017-06-30	Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз	Gp41-нейтрализующие антитела и их применение
CN104271597B (zh)	2011-12-08	2018-05-25	美国政府(由卫生和人类服务部的部长所代表)	Hiv-1的中和抗体及其用途
EP2794658B1 (fr) *	2011-12-19	2017-03-15	Synimmune GmbH	Molécule d'anticorps bispécifique
WO2013163427A1 (fr)	2012-04-25	2013-10-31	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Anticorps pour traiter les infections par le vih-1
US9951106B2 (en)	2012-12-04	2018-04-24	University Of Maryland, Baltimore	Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
US20140213772A1 (en)	2012-12-28	2014-07-31	Abbvie, Inc.	Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
WO2014116846A2 (fr)	2013-01-23	2014-07-31	Abbvie, Inc.	Procédés et compositions pour moduler une réponse immunitaire
WO2014144299A2 (fr)	2013-03-15	2014-09-18	Abbvie Inc.	Protéines de liaison spécifiques à domaines variables doubles dirigées contre tnfα
EP3066133A1 (fr) *	2013-11-04	2016-09-14	Glenmark Pharmaceuticals S.A.	Production de cellules t reciblant des immunoglobulines héréro-dimériques
KR102497443B1 (ko)	2014-03-28	2023-02-08	젠코어 인코포레이티드	Cd38 및 cd3에 결합하는 이중특이적 항체
CN106687584B (zh)	2014-09-04	2021-08-13	干细胞技术公司	用于t细胞或nk细胞活化和扩增的可溶性抗体复合物
AR103268A1 (es) *	2014-12-23	2017-04-26	Bristol Myers Squibb Co	Anticuerpos contra tigit
MY191964A (en)	2015-01-23	2022-07-21	Sanofi Sa	Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2016196740A1 (fr)	2015-06-02	2016-12-08	The Rockefeller University	Anticorps tri-spécifiques pour traitement anti-vih
MX2018005048A (es)	2015-10-25	2018-09-06	Sanofi Sa	Proteinas de union triespecificas y/o trivalantes para la prevencion o el tratamiento de la infeccion por vih.
CN105837688B (zh)	2015-11-20	2019-02-26	北京大学深圳研究生院	单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
BR112018070998A2 (pt) *	2016-04-13	2019-02-26	Sanofi	proteínas de ligação triespecíficas e/ou trivalentes
US12234479B2 (en)	2016-12-30	2025-02-25	Cytocares (Shanghai) Inc.	Bifunctional molecule and use thereof
US10626169B2 (en)	2017-02-17	2020-04-21	Sanofi	Multispecific binding molecules having specificity to dystroglycan and laminin-2
CN120058938A (zh)	2017-10-10	2025-05-30	赛诺菲	抗cd38抗体及与抗cd3和抗cd28抗体的组合
MX2021004147A (es)	2018-10-09	2021-09-08	Sanofi Sa	Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
US11613576B2 (en)	2019-04-09	2023-03-28	Sanofi	Trispecific binding proteins, methods, and uses thereof

2018
- 2018-10-09 CN CN202510116993.7A patent/CN120058938A/zh active Pending
- 2018-10-09 WO PCT/US2018/055084 patent/WO2019074973A2/fr not_active Ceased
- 2018-10-09 MA MA050359A patent/MA50359A/fr unknown
- 2018-10-09 CN CN201880079045.9A patent/CN111788225B/zh active Active
- 2018-10-09 JP JP2020519704A patent/JP7036909B2/ja active Active
- 2018-10-09 EP EP18792827.0A patent/EP3694882B1/fr active Active
- 2018-10-09 SG SG11202003212PA patent/SG11202003212PA/en unknown
- 2018-10-09 AU AU2018348093A patent/AU2018348093A1/en not_active Abandoned
- 2018-10-09 CA CA3078800A patent/CA3078800A1/fr active Pending
- 2018-10-09 EP EP23173927.7A patent/EP4249068A3/fr active Pending
- 2018-10-09 CN CN202311405579.5A patent/CN117964758A/zh active Pending
- 2018-10-09 ES ES18792827T patent/ES2986579T3/es active Active
- 2018-10-09 CN CN202510123093.5A patent/CN120058939A/zh active Pending
- 2018-10-09 KR KR1020207013073A patent/KR20200061402A/ko active Pending
- 2018-10-09 US US16/155,807 patent/US11186649B2/en active Active
- 2018-10-09 BR BR112020007002-5A patent/BR112020007002A2/pt not_active IP Right Cessation
- 2018-10-09 MX MX2020004129A patent/MX2020004129A/es unknown
- 2018-10-09 MY MYPI2020001741A patent/MY199781A/en unknown
- 2018-10-10 UY UY0001037928A patent/UY37928A/es not_active Application Discontinuation
- 2018-10-10 PY PY201801888702A patent/PY1888702A/es unknown
- 2018-10-11 TW TW112139671A patent/TW202432580A/zh unknown
- 2018-10-11 TW TW112124284A patent/TW202342544A/zh unknown
- 2018-10-11 TW TW107135898A patent/TWI821202B/zh not_active IP Right Cessation
- 2018-10-11 TW TW112139669A patent/TW202430563A/zh unknown
2019
- 2019-10-08 AR ARP190102858A patent/AR116718A1/es unknown
2020
- 2020-04-07 IL IL273871A patent/IL273871A/en unknown
- 2020-04-10 PH PH12020550408A patent/PH12020550408A1/en unknown
2021
- 2021-10-15 US US17/503,038 patent/US11365261B2/en active Active
2022
- 2022-03-02 JP JP2022031377A patent/JP7387780B2/ja active Active
- 2022-05-05 US US17/737,814 patent/US20220275102A1/en active Pending
2023
- 2023-11-14 JP JP2023193393A patent/JP7733711B2/ja active Active
2025
- 2025-08-20 JP JP2025136683A patent/JP2025175288A/ja active Pending

Also Published As

Publication number	Publication date
US20220041746A1 (en)	2022-02-10
TW202432580A (zh)	2024-08-16
US20190106504A1 (en)	2019-04-11
TW201930338A (zh)	2019-08-01
AU2018348093A1 (en)	2020-05-28
US20220275102A1 (en)	2022-09-01
KR20200061402A (ko)	2020-06-02
AR116718A1 (es)	2021-06-09
WO2019074973A2 (fr)	2019-04-18
RU2020115450A (ru)	2021-11-15
TW202430563A (zh)	2024-08-01
PH12020550408A1 (en)	2021-04-12
TWI821202B (zh)	2023-11-11
CN117964758A (zh)	2024-05-03
JP2020536543A (ja)	2020-12-17
JP7733711B2 (ja)	2025-09-03
WO2019074973A3 (fr)	2019-06-13
CA3078800A1 (fr)	2019-04-18
MX2020004129A (es)	2020-08-20
SG11202003212PA (en)	2020-05-28
CN111788225B (zh)	2025-02-18
CN111788225A (zh)	2020-10-16
PY1888702A (es)	2020-02-07
EP4249068A3 (fr)	2023-11-22
JP2025175288A (ja)	2025-12-01
JP2022071087A (ja)	2022-05-13
JP7387780B2 (ja)	2023-11-28
BR112020007002A2 (pt)	2020-11-17
ES2986579T3 (es)	2024-11-12
UY37928A (es)	2019-05-31
IL273871A (en)	2020-05-31
EP3694882A2 (fr)	2020-08-19
CN120058938A (zh)	2025-05-30
EP3694882B1 (fr)	2024-06-19
MY199781A (en)	2023-11-23
TW202342544A (zh)	2023-11-01
US11365261B2 (en)	2022-06-21
JP7036909B2 (ja)	2022-03-15
JP2024020377A (ja)	2024-02-14
CN120058939A (zh)	2025-05-30
EP4249068A2 (fr)	2023-09-27
US11186649B2 (en)	2021-11-30

Publication	Publication Date	Title
MA50359A (fr)	2020-08-19	Anticorps anti-cd38 et procédés d'utilisation
MA50956A (fr)	2020-10-14	Anticorps anti-cd137 et procédés d'utilisation correspondants
MA50948A (fr)	2020-10-14	Anticorps et procédés d'utilisation de ceux-ci
MA43018A (fr)	2021-06-02	Anticorps anti-pd1 et procédés d'utilisation
FR24C1050I1 (fr)	2025-01-17	Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation
FR24C1044I2 (fr)	2025-05-23	Anticorps anti-c5 et leurs procédés d'utilisation
MA52753A (fr)	2021-04-21	Anticorps anti-sirpa et leurs procédés d'utilisation
EP3634430A4 (fr)	2021-04-14	Agents multibiotiques et procédés d'utilisation de ceux-ci
MA42043A (fr)	2018-03-14	Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
EP3797123A4 (fr)	2022-03-02	Anticorps anti-ox40 et procédés d'utilisation
EP3612198A4 (fr)	2021-01-13	Bactéries commensales modifiées et procédés d'utilisation
MA53355A (fr)	2022-03-16	Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3710589A4 (fr)	2021-11-10	Anticorps anti-c1s et procédés d'utilisation
MA42925A (fr)	2018-08-01	Anticorps anti-tigit et méthodes d'utilisation
MA45671A (fr)	2021-04-07	Anticorps antivirus zika et procédés d'utilisation
EP3436476A4 (fr)	2020-04-29	Anticorps anti-ryk et leurs procédés d'utilisation
MA46290A (fr)	2019-07-31	Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
MA47849A (fr)	2020-01-29	Anticorps anti-gitr et leurs procédés d'utilisation
MA51552A (fr)	2021-03-24	Anticorps anti-ox40 et procédés d'utilisation
EP3472200A4 (fr)	2020-04-01	Anticorps anti-myostatine et leurs procédés d'utilisation
EP3383914A4 (fr)	2019-10-30	Anticorps anti-ox40 et leurs procédés d'utilisation
EP3491025A4 (fr)	2020-05-27	Anticorps fcrn et leurs procédés d'utilisation
EP3731867A4 (fr)	2022-04-06	Anticorps anti-lrp5/6 et leurs procédés d'utilisation
MA42971A (fr)	2018-08-15	Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MA42979A (fr)	2021-05-26	Anticorps anti-age et procédés d'utilisation correspondants